ACT Brief: Data Pipeline Standardization for Real-Time Analysis, Sponsor Accountability Beyond Contracts, and Autoimmune Pipeline Expansion

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part two of his interview, Raviv Pryluk, CEO and co-founder of PhaseV, explained that the standardization and mapping work transforming raw trial data into analysis-ready formats is the actual bottleneck to real-time monitoring. AI is beginning to automate this transformation process fast enough to make continuous monitoring operationally feasible at scale without sacrificing data validation rigor.
• In part three of her contributed article series, Elizabeth Walsh described how clinical development depends on persistent interdependencies across phases, functions, and vendors that survive formal handoffs. Sponsor oversight cannot be contracted away; treating the CRO agreement as the point where sponsor responsibility ends creates invisible gaps where misalignment accumulates into vendor performance failures or regulatory findings.
• argenx completed the acquisition of Forte Biosciences for $77 per share in cash, representing approximately $2.2 billion equity value. FB102, a first-in-class anti-CD122 antibody showing clinical benefit in vitiligo (vit uh lie go) and celiac disease, brings potential multi-indication impact in autoimmune disease and broadens argenx's immunology mechanism portfolio.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.